Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported a net loss of $34.7 million for the third quarter of 2005, a significant increase from the $11.1 million net loss in the same period of the previous year. This widened loss is partly attributable to increased research and development expenses, particularly in clinical trials, and the adoption of new accounting standards for stock-based compensation, which recognized $5.5 million in expense for the quarter. Revenues declined considerably to $16.2 million from $36.5 million year-over-year, primarily due to decreased collaboration revenue from sanofi-aventis related to the VEGF Trap. The company also announced plans for a workforce reduction, aiming to cut its headcount from 730 to approximately 565 by the end of 2006, which is expected to incur $2.5 million to $3.0 million in severance costs. Financially, the company ended the quarter with $176.1 million in cash and cash equivalents, an increase from $95.2 million at the end of 2004, despite the operating losses. This improved cash position is partly due to upfront payments from collaboration amendments. Looking ahead, Regeneron anticipates continued substantial funding requirements for its ongoing research and development, with a focus on the VEGF Trap for oncology and eye diseases, and the IL-1 Trap for inflammatory indications. The company believes its current capital resources are sufficient through mid-2008, but acknowledges the potential need for additional financing.
Key Highlights
- 1Net loss widened to $34.7 million in Q3 2005 from $11.1 million in Q3 2004, driven by increased R&D expenses and stock-based compensation accounting changes.
- 2Total revenue decreased significantly to $16.2 million in Q3 2005 from $36.5 million in Q3 2004, mainly due to reduced collaboration revenue from sanofi-aventis for the VEGF Trap.
- 3The company announced a workforce reduction plan to cut approximately 165 jobs by the end of 2006, estimating $2.5-$3.0 million in severance costs.
- 4Cash and cash equivalents increased to $176.1 million as of September 30, 2005, up from $95.2 million at the end of 2004, providing a stronger liquidity position.
- 5Significant progress is being made in clinical development, with plans to initiate multiple new trials for the VEGF Trap in oncology and eye diseases, and for the IL-1 Trap in inflammatory indications.
- 6The company is adopting new accounting standards for stock-based compensation (SFAS 123), resulting in recognized expenses that impact reported net income and EPS.
- 7Regeneron expects continued substantial funding requirements for R&D and believes current capital resources are sufficient through mid-2008, but may need additional financing.